Cyclerion to Participate at Upcoming September 2020 Investor Conferences
- Citi’s 15th Annual
BioPharma Virtual Conferenceon September 9th H.C. Wainwright& Co 22nd Annual Global Investment Conferenceon September 16th at 9:30 a.m. ET Cantor Virtual Global Healthcare Conferenceon September 16th and a virtual Fireside Chat on September 17th at 3:20 p.m. ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on
September 21st –23rd on September 21stat 10:50 a.m. ET
A live webcast of the H.C. Wainwright, Cantor, and Oppenheimer presentations can be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Lead programs include its vascular-targeted olinciguat in Phase 2 development for sickle cell disease and IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv)
Kendall Investor Relations
Source: Cyclerion Therapeutics, Inc.